TY - JOUR T1 - Cardiopulmonary exercise testing in interstitial lung disease JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2015.PA4861 VL - 46 IS - suppl 59 SP - PA4861 AU - Christina Priegnitz AU - Lars Hagmeyer AU - Ilona Kietzmann AU - Kerstin Richter AU - Winfried Randerath Y1 - 2015/09/01 UR - http://erj.ersjournals.com/content/46/suppl_59/PA4861.abstract N2 - Background: Interstitial lung diseases (ILD) comprise a heterogeneous group of different entities. Retrospective data show that IPF patients with reduced capacity in cardiopulmonary exercise testing (CET) have a higher mortality (Fell, C. et al. AJRCCM 2009; 179:402-407). Our aim is to evaluate the significance of CET in context of early detection, disease progress and therapy monitoring compared with other pulmonary function tests.Methods: We present a prospective, monocentric, non-interventional longitudinal study. Newly diagnosed ILD patients underwent pulmonary function testing (PFT) including diffusion, arterial blood gases (ABG), 6-minute walk test (6MWT), CET, repeated every 3 months.Results: Until now, baseline data of 20 ILD patients (14 m, 55±15 y, BMI 27.8±4.7 kg/m²) were included. PFT and ABG showed mild restriction (DLCOc 66±16%pred, DLCOcVA 92±16%pred, pO2 75±11mmHg, pCO2 38±4mmHg). 6MWT was normal (415±56m, Borg scale 2±2). Maximum O2 uptake during CET was slightly reduced (89±27%pred), while it was relatively normal at anaerobic threshold in relation to predicted VO2max (52±14%). Respiratory exchange ratio of 1 was reached at 105±41W. Resting AaDO2 was normal (31±13mmHg) and increased disproportionately during exercising (47±18mmHg). During maximal physical strain pulmonary limitation (BR: 14±15L) as well as tachypnea emerged (BF: 39±6/min).Conclusion: Although the ILD patients showed only mild restriction of lung function all patients experienced dyspnea. During exercising, especially AaDO2, BR and BF showed a pathological correlate. It remains to be seen in how far CET is helpful in early detection, follow-up on disease progress and for therapeutical decisions. ER -